Preoperative chemoradiotherapy, surgery and adjuvant therapy for resectable pancreatic cancer

Hidetoshi Eguchi, Hiroaki Nagano, Masahiro Tanemura, Yutaka Takeda, Shigeru Marubashi, Shogo Kobayashi, Koichi Kawamoto, Hiroshi Wada, Naoki Hama, Hirofumi Akita, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background/Aims: In order to improve the poor prognosis of pancreatic cancer, a combination therapy consisting of preoperative chemoradiotherapy, surgery and postoperative chemotherapy may be an ideal strategy; nevertheless, the influence of preoperative therapy to postoperative therapy is not investigated. Methodology: Thirty patients with resectable pancreatic ductal adenocarcinoma were enrolled. A 40Gy of radiation (2Gy/day x 20 fractions/4 weeks) was administered together with intravenous infusion of gemcitabine (800mg/m2, days 1, 8 and 15) before surgery. Surgery was performed 3-7 weeks after the final fraction of radiation, and postoperative chemotherapy consisting of 1000mg/m2 gemcitabine (days 1, 8 and 15 every 4 weeks for 6 cycles) was started within 8 weeks after surgery. Results: All 30 patients successfully completed preoperative therapy. Re-staging after such therapy showed radiologically unresectable disease in 4 patients and 1 patient rejected surgery. Among the 25 patients who underwent laparotomy, 21 underwent curative resection. After curative resection, 4 were inadequate in performance status, thus postoperative therapy could not be started. Ten patients completed postoperative adjuvant therapy. Conclusions: The combination therapy for resectable pancreatic cancer seems a feasible and effective approach, though preoperative therapy may reduce the feasibility of postoperative therapy.

Original languageEnglish
Pages (from-to)904-911
Number of pages8
JournalHepato-Gastroenterology
Volume60
Issue number124
DOIs
Publication statusPublished - Jun 2013
Externally publishedYes

Fingerprint

Adjuvant Chemoradiotherapy
Pancreatic Neoplasms
gemcitabine
Therapeutics
Radiation
Drug Therapy
Chemoradiotherapy
Intravenous Infusions
Laparotomy
Adenocarcinoma

All Science Journal Classification (ASJC) codes

  • Gastroenterology
  • Hepatology

Cite this

Eguchi, H., Nagano, H., Tanemura, M., Takeda, Y., Marubashi, S., Kobayashi, S., ... Doki, Y. (2013). Preoperative chemoradiotherapy, surgery and adjuvant therapy for resectable pancreatic cancer. Hepato-Gastroenterology, 60(124), 904-911. https://doi.org/10.5754/hge12974

Preoperative chemoradiotherapy, surgery and adjuvant therapy for resectable pancreatic cancer. / Eguchi, Hidetoshi; Nagano, Hiroaki; Tanemura, Masahiro; Takeda, Yutaka; Marubashi, Shigeru; Kobayashi, Shogo; Kawamoto, Koichi; Wada, Hiroshi; Hama, Naoki; Akita, Hirofumi; Mori, Masaki; Doki, Yuichiro.

In: Hepato-Gastroenterology, Vol. 60, No. 124, 06.2013, p. 904-911.

Research output: Contribution to journalArticle

Eguchi, H, Nagano, H, Tanemura, M, Takeda, Y, Marubashi, S, Kobayashi, S, Kawamoto, K, Wada, H, Hama, N, Akita, H, Mori, M & Doki, Y 2013, 'Preoperative chemoradiotherapy, surgery and adjuvant therapy for resectable pancreatic cancer', Hepato-Gastroenterology, vol. 60, no. 124, pp. 904-911. https://doi.org/10.5754/hge12974
Eguchi H, Nagano H, Tanemura M, Takeda Y, Marubashi S, Kobayashi S et al. Preoperative chemoradiotherapy, surgery and adjuvant therapy for resectable pancreatic cancer. Hepato-Gastroenterology. 2013 Jun;60(124):904-911. https://doi.org/10.5754/hge12974
Eguchi, Hidetoshi ; Nagano, Hiroaki ; Tanemura, Masahiro ; Takeda, Yutaka ; Marubashi, Shigeru ; Kobayashi, Shogo ; Kawamoto, Koichi ; Wada, Hiroshi ; Hama, Naoki ; Akita, Hirofumi ; Mori, Masaki ; Doki, Yuichiro. / Preoperative chemoradiotherapy, surgery and adjuvant therapy for resectable pancreatic cancer. In: Hepato-Gastroenterology. 2013 ; Vol. 60, No. 124. pp. 904-911.
@article{0510ad67d4af4dec9b73f3501e3b337d,
title = "Preoperative chemoradiotherapy, surgery and adjuvant therapy for resectable pancreatic cancer",
abstract = "Background/Aims: In order to improve the poor prognosis of pancreatic cancer, a combination therapy consisting of preoperative chemoradiotherapy, surgery and postoperative chemotherapy may be an ideal strategy; nevertheless, the influence of preoperative therapy to postoperative therapy is not investigated. Methodology: Thirty patients with resectable pancreatic ductal adenocarcinoma were enrolled. A 40Gy of radiation (2Gy/day x 20 fractions/4 weeks) was administered together with intravenous infusion of gemcitabine (800mg/m2, days 1, 8 and 15) before surgery. Surgery was performed 3-7 weeks after the final fraction of radiation, and postoperative chemotherapy consisting of 1000mg/m2 gemcitabine (days 1, 8 and 15 every 4 weeks for 6 cycles) was started within 8 weeks after surgery. Results: All 30 patients successfully completed preoperative therapy. Re-staging after such therapy showed radiologically unresectable disease in 4 patients and 1 patient rejected surgery. Among the 25 patients who underwent laparotomy, 21 underwent curative resection. After curative resection, 4 were inadequate in performance status, thus postoperative therapy could not be started. Ten patients completed postoperative adjuvant therapy. Conclusions: The combination therapy for resectable pancreatic cancer seems a feasible and effective approach, though preoperative therapy may reduce the feasibility of postoperative therapy.",
author = "Hidetoshi Eguchi and Hiroaki Nagano and Masahiro Tanemura and Yutaka Takeda and Shigeru Marubashi and Shogo Kobayashi and Koichi Kawamoto and Hiroshi Wada and Naoki Hama and Hirofumi Akita and Masaki Mori and Yuichiro Doki",
year = "2013",
month = "6",
doi = "10.5754/hge12974",
language = "English",
volume = "60",
pages = "904--911",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "124",

}

TY - JOUR

T1 - Preoperative chemoradiotherapy, surgery and adjuvant therapy for resectable pancreatic cancer

AU - Eguchi, Hidetoshi

AU - Nagano, Hiroaki

AU - Tanemura, Masahiro

AU - Takeda, Yutaka

AU - Marubashi, Shigeru

AU - Kobayashi, Shogo

AU - Kawamoto, Koichi

AU - Wada, Hiroshi

AU - Hama, Naoki

AU - Akita, Hirofumi

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2013/6

Y1 - 2013/6

N2 - Background/Aims: In order to improve the poor prognosis of pancreatic cancer, a combination therapy consisting of preoperative chemoradiotherapy, surgery and postoperative chemotherapy may be an ideal strategy; nevertheless, the influence of preoperative therapy to postoperative therapy is not investigated. Methodology: Thirty patients with resectable pancreatic ductal adenocarcinoma were enrolled. A 40Gy of radiation (2Gy/day x 20 fractions/4 weeks) was administered together with intravenous infusion of gemcitabine (800mg/m2, days 1, 8 and 15) before surgery. Surgery was performed 3-7 weeks after the final fraction of radiation, and postoperative chemotherapy consisting of 1000mg/m2 gemcitabine (days 1, 8 and 15 every 4 weeks for 6 cycles) was started within 8 weeks after surgery. Results: All 30 patients successfully completed preoperative therapy. Re-staging after such therapy showed radiologically unresectable disease in 4 patients and 1 patient rejected surgery. Among the 25 patients who underwent laparotomy, 21 underwent curative resection. After curative resection, 4 were inadequate in performance status, thus postoperative therapy could not be started. Ten patients completed postoperative adjuvant therapy. Conclusions: The combination therapy for resectable pancreatic cancer seems a feasible and effective approach, though preoperative therapy may reduce the feasibility of postoperative therapy.

AB - Background/Aims: In order to improve the poor prognosis of pancreatic cancer, a combination therapy consisting of preoperative chemoradiotherapy, surgery and postoperative chemotherapy may be an ideal strategy; nevertheless, the influence of preoperative therapy to postoperative therapy is not investigated. Methodology: Thirty patients with resectable pancreatic ductal adenocarcinoma were enrolled. A 40Gy of radiation (2Gy/day x 20 fractions/4 weeks) was administered together with intravenous infusion of gemcitabine (800mg/m2, days 1, 8 and 15) before surgery. Surgery was performed 3-7 weeks after the final fraction of radiation, and postoperative chemotherapy consisting of 1000mg/m2 gemcitabine (days 1, 8 and 15 every 4 weeks for 6 cycles) was started within 8 weeks after surgery. Results: All 30 patients successfully completed preoperative therapy. Re-staging after such therapy showed radiologically unresectable disease in 4 patients and 1 patient rejected surgery. Among the 25 patients who underwent laparotomy, 21 underwent curative resection. After curative resection, 4 were inadequate in performance status, thus postoperative therapy could not be started. Ten patients completed postoperative adjuvant therapy. Conclusions: The combination therapy for resectable pancreatic cancer seems a feasible and effective approach, though preoperative therapy may reduce the feasibility of postoperative therapy.

UR - http://www.scopus.com/inward/record.url?scp=84879592076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879592076&partnerID=8YFLogxK

U2 - 10.5754/hge12974

DO - 10.5754/hge12974

M3 - Article

C2 - 23321032

AN - SCOPUS:84879592076

VL - 60

SP - 904

EP - 911

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 124

ER -